List of Excipients in Branded Drug CERIANNA

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
GE Healthcare Inc	CERIANNA	fluoroestradiol f 18	72874-001	ALCOHOL	1969-12-31
GE Healthcare Inc	CERIANNA	fluoroestradiol f 18	72874-001	SODIUM ASCORBATE	1969-12-31
GE Healthcare Inc	CERIANNA	fluoroestradiol f 18	72874-001	SODIUM CHLORIDE	1969-12-31

CERIANNA Excipient Strategy and Commercial Opportunities in Fluoroestradiol F-18 PET Imaging

Last updated: September 24, 2026

CERIANNA is a fluorine-18 fluoroestradiol injection used for positron emission tomography to detect estrogen receptor-positive lesions in patients with recurrent or metastatic breast cancer. Its formulation is simple: fluoroestradiol F-18 in sterile water for injection with sodium chloride and ethanol. The commercial opportunity is not a conventional excipient-led reformulation play. It is concentrated in radiopharmaceutical manufacturing, sterile supply, container-closure systems, production automation, regional distribution, and next-generation estrogen-receptor imaging agents.

What excipients are used in CERIANNA?

CERIANNA contains a limited excipient system designed for intravenous administration and short product shelf life.

Component	Function	Commercial relevance
Fluoroestradiol F-18	Active radioactive diagnostic agent	PET imaging of estrogen receptor expression
Sodium chloride	Tonicity adjustment	Commodity pharmaceutical ingredient
Ethanol	Co-solvent and formulation aid	Requires control of concentration, residual solvent, flammability and container compatibility
Water for Injection	Vehicle	Sterile compendial vehicle

The FDA-approved product is supplied as an intravenous injection at a radioactive concentration typically calibrated at 148 to 222 MBq/mL, equivalent to 4 to 6 mCi/mL. The label identifies sodium chloride and ethanol as inactive ingredients and specifies storage and handling requirements associated with a radioactive injectable product.[1]

The formulation is not designed for prolonged shelf life. Fluorine-18 has a physical half-life of approximately 109.7 minutes, so the commercial value of the excipient system depends on reliable manufacturing, rapid release, validated transport and administration within a narrow time window.[2]

How does the CERIANNA formulation affect commercial strategy?

CERIANNA has a low-excipient, low-mass formulation. This limits the opportunity to generate value through conventional formulation differentiation.

The principal formulation constraints are:

1. Intravenous tolerability.
2. Chemical and radiochemical stability.
3. Low particulate and endotoxin burden.
4. Compatibility with automated dispensing systems.
5. Low adsorption to syringes, vials and transfer sets.
6. Control of ethanol concentration.
7. Rapid sterility assurance and batch release.
8. Compatibility with short-distance and time-sensitive distribution.

A new excipient is unlikely to create a meaningful commercial advantage unless it improves one of these operating parameters without reducing radiochemical purity or complicating FDA approval.

The stronger opportunity is an excipient and packaging platform that supports multiple fluorine-18 products. Such a platform could be used for CERIANNA, FDG and other PET tracers with similar requirements for sterile delivery, short half-life, automated dose preparation and regional distribution.

What is the regulatory status of CERIANNA?

CERIANNA was approved by the FDA in May 2020 under NDA 212171.[3] The product is indicated for:

• Detection of estrogen receptor-positive lesions in patients with recurrent or metastatic breast cancer.
• Use as an adjunct to biopsy in patients with recurrent or metastatic breast cancer.
• Assessment of estrogen receptor status in patients with recurrent or metastatic breast cancer when metastatic tissue sampling is not feasible or is not recommended.

CERIANNA is not a therapeutic drug and does not replace histopathologic confirmation when biopsy is clinically feasible. Its commercial role is to provide whole-body information on estrogen receptor expression and heterogeneity.

The product is an FDA-approved drug, not an unregulated imaging compound. Manufacturing requires controls for radioactive identity, activity, radiochemical purity, chemical purity, sterility, endotoxins and dose calibration.[1]

What is the FDA exclusivity position?

The principal FDA exclusivity period associated with a 2020 approval would have expired by 2025 if the product received the standard three-year new clinical investigation exclusivity applicable to certain supplemental or new-use approvals. The publicly visible commercial barriers are therefore unlikely to be driven by remaining FDA exclusivity alone.

For CERIANNA, the more important barriers are:

• An approved NDA and chemistry, manufacturing and controls package.
• Access to fluorine-18 production.
• Qualified PET manufacturing sites.
• Validated synthesis and dispensing equipment.
• Radiopharmacy licenses and radiation-safety infrastructure.
• Time-sensitive delivery to imaging centers.
• Reimbursement and physician adoption.

What is the Orange Book status of CERIANNA?

CERIANNA is listed by the FDA as an approved NDA product. The commercial significance of Orange Book patent listings is limited compared with conventional oral or injectable small-molecule medicines because the principal entry barriers are manufacturing and distribution rather than formulation exclusivity.[3,4]

A competitor could face regulatory requirements for an abbreviated or 505(b)(2) pathway, depending on the proposed product, manufacturing process and reliance on the reference product. A competing fluorine-18 fluoroestradiol product would still need to demonstrate pharmaceutical quality, radiochemical performance, sterility and an acceptable clinical and imaging basis.

There is no obvious indication that sodium chloride, ethanol or water for injection creates a standalone patent barrier around CERIANNA. These components are established pharmaceutical excipients. Any defensible intellectual property would more likely concern:

• Precursor chemistry.
• Radiolabeling methods.
• Automated synthesis.
• Purification.
• Cartridge or cassette architecture.
• Dose dispensing.
• Quality-control analytics.
• Specific imaging applications.
• Manufacturing logistics.

What excipient patents could protect a competing CERIANNA formulation?

A conventional excipient patent is unlikely to provide strong protection because the formulation is simple and the excipients are widely used. The more credible patent opportunities are process and device claims.

Formulation patents

Potential formulation claims could address:

• Defined ethanol concentration ranges.
• Radiolysis control.
• pH control.
• Specific antioxidant systems.
• Reduced adsorption to polymeric components.
• Low-volume multidose or unit-dose presentations.
• Compatibility with automated dose injectors.
• Stabilized formulations with improved radiochemical purity at end of shelf life.

The difficulty is that any added excipient must be justified for an injectable radioactive product. Antioxidants, buffers or surfactants could introduce toxicity, impurity, extractables or regulatory complications. A formulation that materially increases stability may also require new analytical methods and clinical bridging.

Container-closure patents

Container and delivery-system IP is more commercially credible than a new excipient. Relevant technologies include:

• Low-dead-volume vials.
• Radiation-compatible elastomeric stoppers.
• Low-binding syringes.
• Shielded unit-dose containers.
• Closed transfer systems.
• Automated dispensing interfaces.
• Barcoded containers for activity and patient-dose reconciliation.
• Materials with reduced fluorine-18 adsorption.

These technologies can create value across several PET products, not only CERIANNA.

Manufacturing patents

Manufacturing and automation claims could cover:

• Preassembled single-use cassettes.
• Remote synthesis and purification.
• Automated quality-control release.
• Integrated dose calibration.
• Reduced operator exposure.
• Improved precursor recovery.
• Shorter synthesis-to-injection time.
• Regional production using compact cyclotron networks.

Such claims can protect a business model even when the final formulation uses standard excipients.

How strong is the CERIANNA patent estate?

The commercial patent strength of CERIANNA appears weaker than that of a conventional branded oncology medicine if assessed solely through excipient and formulation claims. The product’s defensibility is more likely to come from know-how, regulatory execution and supply-chain density.

Protection category	Likely strength	Strategic assessment
Sodium chloride formulation	Low	Established excipient with limited differentiation
Ethanol formulation	Low to moderate	Potential value in concentration, stability and compatibility ranges
Container closure	Moderate	Can protect delivery performance and reduce operational losses
Automated synthesis	Moderate to strong	May create defensible manufacturing advantages
Radiopharmacy distribution	Strong operational barrier	Difficult to replicate at scale because of half-life
Clinical imaging evidence	Moderate	Supports adoption and payer discussions
FDA NDA	Moderate	Creates regulatory reference-product value
Method-of-use claims	Moderate	May protect specific ER imaging workflows
Ingredient supply	Low individually	Importance increases through qualified-vendor controls

Patent strength should therefore be assessed as a combined formulation, process, device and commercial infrastructure portfolio rather than as an excipient patent alone.

What commercial opportunities exist for excipient suppliers?

Can commodity excipients generate meaningful revenue?

Sodium chloride, ethanol and water for injection are low-cost inputs. Direct ingredient sales to one CERIANNA manufacturing site would not normally produce material revenue unless the supplier provides validated sterile grades, rapid delivery, small-batch support or bundled radiopharmaceutical services.

The better opportunity is to sell qualified excipient systems across a portfolio of PET tracers.

Potential offerings include:

• Sterile ethanol in radiopharmaceutical-grade packaging.
• Low-bioburden sodium chloride solutions.
• Single-use sterile formulation assemblies.
• Prequalified water-for-injection components.
• Low-extractables vials and stoppers.
• Syringes designed for radioactive dose handling.
• Ready-to-use sterile transfer kits.
• Stability and compatibility testing.
• Regulatory documentation for excipient qualification.

Which excipient has the greatest strategic value?

Ethanol is the most commercially relevant formulation component because it can affect solubility, product compatibility, residual solvent control and container interaction. Its value remains limited as a standalone molecule but increases when supplied with:

• Defined pharmaceutical-grade specifications.
• Low aldehyde and peroxide impurities.
• Controlled water content.
• Validated sterilization or sterile filtration strategy.
• Packaging that limits evaporation.
• Compatibility data with vials, syringes and automated injectors.

Sodium chloride and water for injection are more likely to be bundled into a complete sterile manufacturing system than sold as differentiated ingredients.

What manufacturing and IP barriers limit generic CERIANNA entry?

Generic or follow-on entry is constrained by the physical properties of fluorine-18.

Short half-life

A product cannot be manufactured centrally and distributed over a wide geographic area in the same way as a conventional injectable. Each dose must move rapidly from production to imaging.

Cyclotron access

A commercial operator generally needs access to a cyclotron or a regional supplier of fluorine-18. This creates local-market barriers and favors networks with established PET infrastructure.

Radiochemistry

Manufacturers need validated radiolabeling and purification processes. The process must achieve acceptable radiochemical purity within a short production cycle.

Quality control

Release testing must be rapid. Conventional long-duration sterility testing is not operationally compatible with a short-lived product, so manufacturers rely on validated aseptic processing, environmental control and rapid quality testing.

Radiation safety

Manufacturing and dispensing require shielding, dosimetry, licensed facilities and trained personnel. These requirements increase capital expenditure and limit the number of qualified sites.

Reimbursement

Clinical adoption depends on whether physicians and payers recognize the value of ER imaging relative to biopsy, FDG PET and other diagnostic pathways. Reimbursement is a larger commercial variable than excipient cost.

How does CERIANNA compare with competing imaging options?

Option	Primary use	Commercial advantage	Limitation
CERIANNA	Whole-body ER expression imaging	Noninvasive assessment of ER-positive disease	Requires PET infrastructure and radiopharmaceutical production
FDG PET	Glucose metabolism imaging	Broad availability and established use	Does not directly measure ER expression
Biopsy	Direct tissue assessment	Histologic and molecular confirmation	Invasive and may not capture tumor heterogeneity
Other ER imaging agents	ER-targeted imaging	Potential clinical differentiation	May have limited approval or supply

CERIANNA’s commercial positioning is strongest where metastatic tissue is difficult to obtain, receptor heterogeneity is clinically relevant or a whole-body assessment can affect treatment selection.

What licensing and partnership opportunities exist?

The most attractive licensing targets are unlikely to involve the basic excipients. They are more likely to involve the manufacturing and delivery chain.

Potential transactions include:

1. Licensing automated synthesis cassettes to regional PET manufacturers.
2. Supplying qualified sterile excipient assemblies to radiopharmaceutical producers.
3. Partnering with cyclotron operators for local CERIANNA production.
4. Licensing low-adsorption container systems to radiopharmacy networks.
5. Providing quality-control software and dose-tracking systems.
6. Developing companion imaging agents for other hormone receptors.
7. Establishing co-development arrangements for next-generation F-18 ER tracers.

A supplier with validated packaging, rapid-release analytics and radiopharmacy distribution capability could capture more value than a supplier selling ethanol or sodium chloride alone.

What generic launch scenarios are most plausible?

Scenario 1: Local compounded F-18 fluoroestradiol

A regional radiopharmacy could produce a comparable tracer for local use. This is the most plausible competitive pathway but requires validated manufacturing, regulatory compliance and reliable clinical demand.

Scenario 2: FDA-approved follow-on product

A sponsor could pursue an NDA or 505(b)(2)-type strategy for a comparable fluoroestradiol F-18 injection. The product would need a credible quality and clinical bridge to the reference product.

Scenario 3: Alternative ER-targeted tracer

A competitor could avoid direct formulation competition by developing a different ER-targeted radiopharmaceutical with improved production, distribution or imaging characteristics.

Scenario 4: Platform competition

A radiopharmacy network could compete through supply reliability, lower dose wastage, shorter delivery times and better integration with imaging centers. This may be more commercially effective than attempting to differentiate standard excipients.

Key Takeaways

• CERIANNA uses a simple formulation based on fluoroestradiol F-18, sodium chloride, ethanol and water for injection.
• Excipients are unlikely to provide strong standalone exclusivity.
• Ethanol has the greatest formulation relevance, but its commercial value depends on validated concentration, purity and container compatibility.
• Container-closure systems, automated dispensing, rapid quality control and synthesis cassettes offer stronger IP and commercial opportunities.
• Fluorine-18’s short half-life makes regional production and distribution a central competitive barrier.
• The strongest business model is a multi-product radiopharmaceutical platform rather than a CERIANNA-only excipient supply agreement.
• FDA approval, cyclotron access, radiochemistry capability, radiation safety and reimbursement are more important than raw excipient cost.
• Generic entry is operationally possible but difficult to scale nationally because production must remain close to PET imaging demand.

FAQs About CERIANNA Excipient Strategy

Is CERIANNA an oncology treatment?

No. CERIANNA is a diagnostic radiopharmaceutical used for PET imaging of estrogen receptor-positive lesions in recurrent or metastatic breast cancer.

Does CERIANNA contain a preservative?

The FDA labeling identifies sodium chloride, ethanol and water for injection as inactive formulation components. The product is not positioned as a conventional multidose preserved injectable.[1]

Can a company patent a new CERIANNA excipient formulation?

A company could seek claims covering a defined formulation, stability range or container interaction. The strongest protection would likely require a measurable technical benefit, such as improved radiochemical stability or reduced adsorption.

What is the largest cost driver in CERIANNA manufacturing?

The largest costs are likely to arise from cyclotron and radiochemistry operations, qualified personnel, facility compliance, quality control, dose wastage and time-sensitive distribution rather than sodium chloride or water for injection.

Is biosimilar competition relevant to CERIANNA?

No. CERIANNA is a small-molecule radioactive diagnostic drug, not a biologic. Competitive risk would come from generic, compounded or alternative radiopharmaceutical products rather than biosimilars.

References

1. U.S. Food and Drug Administration. (2023). CERIANNA (fluoroestradiol F 18 injection) prescribing information. FDA.

2. National Institute of Standards and Technology. (n.d.). Fluorine-18 decay data. NIST.

3. U.S. Food and Drug Administration. (2020). FDA approves new imaging drug to help evaluate breast cancer. FDA.

4. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. FDA.